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Abstract
The calcium-sensing receptor (CaSR) plays a pivotal role in systemic calcium metabolism by regulating parathyroid
hormone secretion and urinary calcium excretion. The diseases caused by an abnormality of the CaSR are
genetically determined or are more rarely acquired. The genetic diseases consist of hyper- or hypocalcemia
disorders. Hypercalcaemia disorders are related to inactivating mutations of the CASR gene either heterozygous
(autosomal dominant familial benign hypercalcaemia, still named hypocalciuric hypercalcaemia syndrome type 1) or
homozygous (severe neonatal hyperparathyroidism). The A986S, R990G and Q1011E variants of the CASR gene are
associated with higher serum calcium levels than in the general population, hypercalciuria being also associated
with the R990G variant. The differential diagnosis consists in the hypocalciuric hypercalcaemia syndrome, types 2
(involving GNA11 gene) and 3 (involving AP2S1 gene); hyperparathyroidism; abnormalities of vitamin D metabolism,
involving CYP24A1 and SLC34A1 genes; and reduced GFR. Hypocalcemia disorders, which are more rare, are related
to heterozygous activating mutations of the CASR gene (type 1), consisting of autosomal dominant hypocalcemia
disorders, sometimes with a presentation of pseudo-Bartter’s syndrome. The differential diagnosis consists of the
hypercalciuric hypocalcaemia syndrome type 2, involving GNA11 gene and other hypoparathyroidism aetiologies.
The acquired diseases are related to the presence of anti-CaSR antibodies, which can cause hyper- or especially
hypocalcemia disorders (for instance in APECED syndromes), determined by their functionality. Finally, the role of
CaSR in digestive, respiratory, cardiovascular and neoplastic diseases is gradually coming to light, providing new
therapeutic possibilities. Two types of CaSR modulators are known: CaSR agonists (or activators, still named
calcimimetics) and calcilytic antagonists (or inhibitors of the CasR). CaSR agonists, such as cinacalcet, are indicated
in secondary and primary hyperparathyroidism. Calcilytics have no efficacy in osteoporosis, but could be useful in
the treatment of hypercalciuric hypocalcaemia syndromes.
Keywords: CASR, Hyperparathyroidism, Hypercalcaemia, Hypocalcemia, Hypercalciuria, Hypocalciuria,
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Background
The calcium-sensing receptor (CaSR), a G-protein coupled
receptor (GPCR) family member, is ubiquitously expressed,
but mostly in the parathyroid gland and the renal tubule. It
enables CaSR-expressing cells to sense alterations in the
level of blood calcium and to normalize its concentration,
by regulating parathyroid hormone (PTH) secretion and
urinary calcium excretion. The CaSR is able to bind
numerous ligands, to interact with multiple G-proteins,
and to regulate highly divergent downstream signalling
pathways and cell fate, through epigenetics and miRNA [1].
Besides Ca2+, the ligands include other divalent cations
such as Mg2+, Ba2+, Mn2+, Ni2+, Sr2+ and trivalent cations
La3+ and Gd3+, basic peptides (such as poly-arginine, pro-
tamine, and poly-lysine), glutathione and its γ-glutamyl
peptides, agonists (such as AMG 416), antagonists and
drugs [2]. The human CASR gene localizes on chromosome
3q and has 8 exons, the first (1A and 1B) encoding alterna-
tive 5′-untranslatesd regions splicing. The CASR promoters
are responsive to 1,25-dihydroxyvitamin D, proinflamma-
tory cytokines (TNF-alpha, IL-1beta and IL-6) and the tran-
scription factor glial cells missing-2 (GCM2) [1]. Abnormal
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CaSR function affects the development of both calciotropic
disorders, and non-calciotropic disorders, such as cardio-
vascular disease and cancer [3].
Several disorders of calcium sensing arise from inherited
or acquired abnormalities that ‘reset’ the serum calcium
concentration upwards or downwards. They are expressed
through a hyper- or hypocalcaemic syndrome [3] (Table 1).
Familial hypocalciuric hypercalcaemia syndromes are
schematically related to inactivating mutations of the
CASR gene:
– heterozygous (benign familial hypercalcaemia)
– homozygous (neonatal hyperparathyroidism)
Hypocalcaemia, which is more rare, is related to hetero-
zygous activating mutations of CASR, corresponding to
autosomal dominant hypocalcaemia, sometimes with a
presentation of pseudo-Bartter’s syndrome. Acquired
diseases, which are much more rare, are associated with the
presence of CaSR-stimulating or CaSR-blocking antibodies.
Finally, the role of CaSR in many diseases that do not
cause calcium and phosphate disorders is gradually
coming to light, thus providing new therapeutic
possibilities.
The aim of this review is 1) to make a point on the
different disorders of calcium metabolism associated
with CaSR anomalies, their main differential diagnoses,
and their treatment, 2) to unveil the less known fields in
which the CaSR could be involved. To do so, we
performed a literature review with the keywords
calcium-sensing receptor, hypocalciuric hypercalcaemia,
hypocalcemia and hyperparathyroidism.
Genetic causes
Hypercalcaemia via inactivating CASR mutations
Heterozygous inactivating mutations
Typical clinical and laboratory presentation Hetero-
zygous inactivating CASR mutations result in a familial
hypocalciuric hypercalcaemia syndrome (FHH) consist-
ing of:
– moderate hypercalcaemia, usually below 1.25 mmol/L,
– a relative hypocalciuria with calcium to creatinine
clearance ratio below 0.01, with a gray zone
between 0.011 and 0.019 when the diagnosis is
still possible [4, 5],
– a normal or high plasma PTH value,
– the usual absence of complications related to this
hypercalcaemia.
Familial hypocalciuric hypercalcaemia syndrome, also
known as FHH1, familial benign hypercalcaemia or
Marx-Auerbach syndrome, is usually transmitted as an
autosomal dominant trait. The hypercalcaemia is moder-
ate and asymptomatic, although it may be marked and/
or clinically evident in 10% of cases. It persists through-
out the patient’s life. Plasma PTH is normal in 80% of
cases and is therefore maladjusted to the serum calcium
levels. Moderate hypermagnesemia is often seen. A
family history of hypercalcaemia should be investigated
through the plasma assay of serum calcium in relatives.
Clinical forms Although this form of hypercalcaemia is
usually asymptomatic, cases of pancreatitis and chondro-
calcinosis have been reported in some adults [6].
An increase in parathyroid volume is generally not seen.
However, a dozen cases of parathyroid adenomas associated
with CASR mutations have been reported, with two families
having adenoma and/or familial hyperplasia of the parathy-
roids with papillary microcarcinoma [7–14]. Moreover, the
R990G variant of CaSR seems to be more common in the
general Chinese population, but also in Chinese patients
with hyperparathyroidism [15]. The coexistence of hyper-
parathyroidism and hypocalciuric hypercalcaemia syndrome
was also identified in 4 out of 139 patients from a hyper-
parathyroid Caucasian population [16]. The serum calcium
levels decreased postoperatively. These associations remain
rare and may be found fortuitously. Nevertheless, mutant
sensors in the plasma membrane have been shown to be
major contributors to hyperplasia of parathyroid glands [17].
Also, a tendency for hypercalciuria has been reported with
the R990G variant, also resulting in slightly higher serum
calcium levels than in the general population [18–20].
Finally, some cases of recessive inheritance have been
reported [21, 22].
Table 1 Main diseases related to CaSR anomalies
Hypocalciuric hypercalcaemia syndromes:
- Genetic via inactivating mutations of the CASR gene
o heterozygous (familial benign hypercalcaemia),
NB: Serum calcium levels of the variants A986S, R990G and Q1011E
slightly higher than in the general population
o homozygous, compound heterozygous (severe neonatal
hyperparathyroidism)
- Acquired via anti-CaSR blocking antibodies (rare)
Hypercalciuric hypocalcaemia syndrome, more rare,
- Genetic via heterozygous activating mutations of the CASR gene
o autosomal dominant
o sometimes with presentation of pseudo-Bartter’s syndrome
- Acquired via anti-CaSR stimulating antibodies
Other disorders
- Hypercalciuria - lithiases R990G variant of CaSR




- Inflammatory digestive and respiratory diseases
- Taste (kokumi)
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Differential diagnosis The differential diagnosis con-
sists of the hypocalciuric hypercalcaemia syndrome types
2 and 3; hyperparathyroidism, familial in particular;
abnormalities of vitamin D metabolism; and reduced
GFR (glomerular filtration rate) (Table 2).
– Hypocalciuric hypercalcaemia syndrome type 2 is
linked to mutations of the GNA11 gene, located on
chromosome 19p13.3 and coding for one of the
sub-units of the G-protein (G-α11). This forms
comprises about 10% of familial benign hypercalcae-
mia cases [23].
– Type 3 consists of mutations of the AP2S1 gene,
also located on chromosome 19 but at 19q13.3,
generally at the level of arginine in position 15.
AP2S1 mutations account for about 20% of
familial hypocalciuric hypercalcaemia cases. This
form is associated with a more severe FHH
variant that may lead to symptomatic
hypercalcaemia with hypophosphoraemia and an
increase of PTH with age, low bone mineral
density and cognitive dysfunction.,. The AP-2
complex is a heterotetramer composed of α, β, μ
and σ sub-units binding clathrin to the vesicle
membranes. These vesicles intervene in the internal-
isation of the receptors coupled with the G-proteins
(GPCRs). Mutations of the σ sub-unit of AP2 decrease
the sensitivity of the cells to the extracellular calcium
and reduce CaSR endocytosis [24, 25].
– About 20% of hypocalciuric hypercalcaemia
syndrome cases are not related to the identified
genes, suggesting that still unknown genes are
probably involved [26].
Besides the mutations of the genes involved in types 2
and 3 FHH, FHH syndromes related to a mutation of
the CASR gene must be differentiated from hyperpara-
thyroidism with normal PTH [27].
In the hypocalciuric hypercalcaemia syndromes, the
familial character of the hypercalcaemia and a calcium
to creatinine clearance ratio below 0.01 support familial
benign hypercalcaemia rather than hyperparathyroidism,
despite a gray zone.
There are also other autosomal dominant genetic
forms of familial hypercalcaemia, which are associated
with different syndromic manifestations such as tumours
and particularly hyperparathyroidism linked to tumour
suppressor gene mutations, including:
– the MEN1 gene, coding for menin in multiple
endocrine neoplasia type 1 (MEN1),
– the HRPT2 (/CDC73) gene, specifically involved in
carcinogenesis,
– the CDKN1B gene,
– but also the APC, SFRPs, GSK3β, RASSF1A, HIC1,
RIZ1, andWT1 genes, and possibly CASR [28],
GNA11, AP2S1, and GCM2 or glial cells Missing-2, a
transcription factor linked to the early development pf
parathyroid glands [1, 29]
as well as mutations of proto-oncogenes (CCND1/
PRAD1, RET in MEN2, ZFX, CTNNB1, EZH2) [30–32].
Finally, mutations of the CYP24A1 gene with autosomal
recessive transmission may induce a biological phenotype,
characterized by hypercalcemia, hypercalciuria, depressed
PTH, normal 25-OHD, increased 1-25-(OH)2D, and
decreased 24-25-(OH)2D3 levels, characteristic of infant-
ile hypercalcemia, which may also be related to
SLC34A1 gene mutations. Late-onset forms include
nephro-lithiasis/-calcinosis, chronic renal insufficiency
and hypertension. The CYP24A1 gene belongs to the
CYP450 group and encodes for 25-hydroxyvitamin D
(25-OHD) 24-hydroxylase, a key enzyme of calcitriol
(1-25-(OH)2D) degradation. Reduced rates of inactiva-
tion of 1-25-(OH)2D caused by a CYP24A1 gene defect
result in increased serum 1-25-(OH)2D levels and
Table 2 Main differential diagnoses of calcium disorders related
to CASR gene mutations
Hypercalcaemia
Familial hypocalciuric hypercalcaemia (FHH) syndromes
- type 2 via mutations of the GNA11 gene (10%)
- type 3 via mutations of the AP2S1 gene (15%)
- via mutations of other as of yet unknown genes (20%)
Familial hyperparathyroidism
- via mutations of tumour suppressor genes:
o MEN1 (Multiple endocrine neoplasia type 1)
o HRPT2 (/CDC73)
o CDKN1B (MEN4)
o but also the APC, SFRPs, GSK3β, RASSF1A, HIC1, RIZ1, and WT1 genes,
and possibly CASR, GNA11, AP2S1, and GCM2…
- via mutations of proto-oncogenes (CCND1/PRAD1, RET [MEN2], ZFX,
CTNNB1, EZH2)cpe
Hyperparathyroidism with normal or low PTH with hypercalciuria via
mutation of the genes
- CYP24A1
- SLC34A1
Hypercalcemia associated with reduced glomerular filtration rate,
making the low urine calcium difficult to interpret
Hypocalcaemia
Hypercalciuric hypocalcaemia syndrome type 2 via activating mutation
of the GNA11 gene.
No gain-of-function mutation described for the AP2S1 gene
Other types of hypoparathyroidism
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intestinal absorption of calcium, causing down-
regulation of PTH secretion [33]. Two cases of hyper-
parathyroidism complicating CYP 24A1 mutations have
been reported [34].
Treatment Calcimimetics as a rule are not indicated
except in case of symptomatic forms. It is important to
remember to investigate for parathyroid adenoma in the
event of complications.
Homozygous inactivating mutations
Clinical and laboratory presentation The homozygous
inactivating mutations of CASR [35, 36], which are much
more rare, may result in severe neonatal hyperparathyr-
oidism (NSHPT) with:
– marked hypercalcaemia,
– most of the time hypercalciuria, when very high
PTH and calcium levels increase renal calcium
excretion, with values of calcium/creatinine





Neonatal hyperparathyroidism is a severe life-threatening
disorder. The role of normal maternal serum calcium levels
perceived as being low by the newborn could promote the
occurrence of this hyperparathyroidism, by stimulating
PTH secretion, early during the intra-uterine life. The
increased level of serum calcium leads to hypercalciuria.
Otherwise NSHPT is associated with a large pro-
portion of CASR mutations involving the Ca2+ -bind-
ing sites particularly at the VFTD cleft, which is the
principal site of Ca2+ binding [37]. Mutant sensors
in the plasma membrane are major contributors to
hyperplasia, which is usually observed in the four
glands in NSHPT [17]. The main mutations reported
in this condition are compound homozygous or
heterozygous inactivating mutations of CASR or
sometimes simply de novo occurring heterozygotes
[37, 38], such as the R185Q and R227Q mutations,
which are the cause of alterations in the MAP-
kinase (MAPK) pathway.
Progression Progression generally follows the familial
benign hypercalcaemia pattern. Variants of this severe
hypercalcaemia have been described with a later appear-
ance in childhood, particularly in the case of compound
heterozygosity of the CASR gene inherited from the par-
ents each having asymptomatic familial benign
hypercalcaemia, whereas inbred parents rather lead to
homozygote children.
Finally, significant negative feedback from the protein
coded by the CASR gene has ben reported in a consider-
able proportion of parathyroid carcinoma cases having a
high proliferation index. In contrast, no mutation of the
CASR gene has been demonstrated in these parathyroid
carcinomas.
Treatment Besides rehydratation with normal saline,
treatment is based on cinacalcet (which is not always
effective), biphosphonates, low-calcium milk and, as a
last resort, on total parathyroidectomy [39].
Hypocalcaemia via activating mutations of CASR
Hypercalciuric hypocalcaemia syndrome type 1
Hypercalciuric hypocalcaemia syndrome is an iso-
lated form of autosomal dominant, congenital hypo-
parathyroidism that is the mirror of the presentation
of FHH (Table 1). There is therefore hypocalcemia
with normal or low PTH but that is maladjusted in
all cases. The urine calcium is usually normal, con-
sistent with hypercalciuria relative to the serum
calcium levels. There is a tendancy for hypomagnes-
emia. This syndrome is linked to gain-of-function, or
activating, mutations of the CASR gene [40–42].
– 50% of patients present with moderate and
asymptomatic hypocalcemia that is found
fortuitously,
– 50% present with paresthesias, tetany, epilepsy,
severe hypocalcaemia, sometimes with Bartter
syndrome [43],
– 10% present with hypercalciuria with
nephrocalcinosis or lithiasis,
– Over 35% present with ectopic and/or basal ganglia
calcifications.
The A843E, C131W, F788C mutations are generally
associated with hypomagnesemia with PTH at the lower
limit of normal. The P221L, K47N and finally E481K
mutations are associated with normal serum magnesium
levels, and an increased PTH in response to the hypocal-
cemia [44, 45].
Differential diagnosis
The differential diagnosis of these hypercalciuric hypocal-
caemia syndromes consists of the hypercalciuric hypocal-
caemia syndrome type 2 linked to a gain-in-function
activating mutation of the GNA11 gene (Table 2). The
phenotype is identical to the hypercalciuric hypocalcae-
mia syndrome type 1 linked to an activating mutation
of the CASR gene, apart from the hypercalciuria and
hypomagnesemia that are not present in the type 2
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form, [41, 46]. A gain-of-function mutation has still not
been described for the AP2S1 gene at this time.
The other differential diagnoses consist of hypopara-
thyroidism aetiologies.
This presentation may be reproduced by the presence
of anti-CaSR stimulant antibodies, for which an investi-
gation will therefore need to be done.
Clinical forms
Bartter-like phenotype A Bartter-like phenotype of
these CASR activating mutations results in a presenta-
tion of hypokalemic metabolic alkalosis, with moderate
secondary hyperaldosteronism without very severe salt
loss, but with a tendancy for hypercalciuric hypocalce-
mia. This presentation has been described in several
adults and several children [43, 44].
It consists of mutations that are generally highly
activating of the CASR gene, e.g. L125P.
The pathophysiology is related to CaSR activation,
which inhibits the reuptake of sodium chloride by means
of the thiazide-sensitive sodium chloride transporter.
This effect is not visible when the mutation is only
slightly activating, but becomes so when it is significant.
In this situation, the mutations that are usually
responsible for Bartter syndrome (NKCC2, ROMK,
CLCKB et BSND) are negative.
Sporadic hypoparathyroidism There are cases of spor-
adic hypoparathyroidism that are identical to the auto-
somal dominant hypercalciuric hypocalcemia syndrome,
except that the familial influence is lacking. These are
therefore de novo CASR mutations, and must be differ-
entiated from an autoimmune cause. The hypocalcemia
may have few symptoms or may otherwise be very
debilitating or even life-threatening. Few cases have been
described.
Treatments
The emergency treatment for these types of hypocalcae-
mia is based on parenteral calcium administration and
the standard of care treatment would be vitamin and
calcium supplementation. Vitamin D stimulates the
expression of CASR but causes an increase in urine
calcium with the risk of nephrocalcinosis in 57% of
treated subjects.
For this reason, it is recommended that treatment
should only be given to patients with hypocalcaemia
below 76 mg/L and/or who are symptomatic, using the
smallest dose of 1 alpha-hydroxycholecalciferol (1 to
2 μg/day), while monitoring the 24-h urine calcium
every 3 to 6 months. The combination with thiazides, to
decrease the urine calcium, worsens the hypokalemic
tendency [26]. Recombinant PTH may normalise the
serum and urine calcium levels. Calcilytic compounds
(allosteric inhibitors of CaSR) could be beneficial in the
future, through stimulation of PTH secretion and reduc-
tion of urine calcium and renal calcifications [47, 48].
They are however usually ineffective in osteoporosis.
Otherwise, certain drugs such as proton pump inhibitors
may worsen hypomagnesemia and hypocalcemia and




The clinical presentation of autoimmune hypocalciuric
hypercalcaemia is identical to the presentation of the
genetically determined forms, with moderate hyperpara-
thyroidism, relative hypocalciuria, and inappropriate
PTH. An association with other autoimmune diseases is
possible in the case of autoimmune polyendocrinopathy
syndrome type 1 (APECED) or type 2 (particularly
thyroid diseases and coeliac disease). The case studied
histologically did not show lymphocytic infiltration of
the parathyroids. Anti-CaSR antibodies, blocking in
vitro, directed against the extracellular portion of the
protein have been identified [49–51]. They inhibit the
activation of CaSR by the extracellular calcium, resulting
in PTH stimulation.
Acquired autoimmune hypoparathyroidism
These types of hypoparathyroidism may occur in isolation
or in association with autoimmune polyendocrinopathy
type 1 or more rarely with type 2. They are characterised
by the presence of antibodies directed against the extracel-
lular portion of CaSR. The prevalence of these antibodies
in isolated autoimmune hypoparathyroidism is about 49%.
The presence of this type of antibody does not imply that
they are necessarily functional.
Anti-NALP5 antibodies have also been identified, par-
ticularly in cases of hypoparathyroidism related to the
APECED syndrome. Their specificity is 50% and their
sensitivity is 26%, which makes them a poorer indicator
than the anti-CaSR antibodies,which have a specificity of
83% and a sensitivity of 50%. The presence of these anti-
bodies in this type of syndrome is more frequent when
they are assayed early relative to the date of occurrence
of the hypoparathyroidism [50].
Calcium-sensing receptor and other diseases
Hypercalciuria and lithiasis
The serum calcium level is genetically determined for 50
to 70% of its variability. The A986S variant, as well as
the R990G and Q1011E variants, are associated with
higher serum calcium levels [27, 28] than in the general
population. Hypercalciuria is associated with the R990G
variant of CASR [18–20]. The minor allele rs6776158
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predisposes to kidney stones by decreasing the transcrip-
tional activity of the CASR gene promoter 1 and its
renal tubular expression. Moreover, Claudin 14, a pro-
tein which regulates the transport of ions ans solutes at
epithelial tight junctions, is expressed at a lower level in
the rs6776158 GG homozygous subjects. In these cases,
nephrolithiasis may occur by another mechanism than
hypercalciuria [1, 19].
Calcium-sensing receptor and the digestive tract
Hypercalcaemia is associated with increased acid discharge,
since the secretion of gastrin and calcitonin is stimulated by
the hypercalcaemia via the intermediary of the CaSR
present in the gastrin-secreting cells. Patients presenting
with hypercalcaemia therefore have a frequent tendency for
hypergastrinaemia, which may explain the increased
frequency of digestive disorders. CaSR reportedly has anti-
inflammatory, anti-secretory, pro-absorbent and inhibitory
properties on intestinal motility. Its activation could provide
a new therapeutic approach for diarrhoea [52, 53].
Calcium-sensing receptor and the respiratory tract
The activation of CaSR also reportedly has anti-
inflammatory and anti-allergic properties, which could
provide a therapeutic benefit [54].
Calcium-sensing receptor and cancer
A correlation was observed between certain CASR
rs17251221 type polymorphisms and coronary artery
disease, type 2 diabetes, cancer and mortality. In cancer,
CaSR appears to have paradoxical roles, and depending
on the tissue involved, it is able to prevent or promote
tumour growth. This effect would be mediated through
genetic or epigenetic mechanisms such as methylation
of the CASR P2 promoter especially in colon cancer and
neuroblastic tumors [1]. In tissues like the parathyroid
or colon, CaSR inhibits proliferation and induces
terminal differentiation of the cells. Therefore, loss of
the receptor, as seen in colorectal or parathyroid
tumours, confers malignant potential, suggestive of a
tumour suppressor role. In contrast, in prostate and
breast tumours, expression of CaSR is increased, and it
seems that it favours metastasis to the bone, acting as an
oncogene [55, 56]. Normal and neoplastic mammary
epithelial cells express CaSR. During lactation, CaSR
activation in the mammary cells causes negative feed-
back of parathyroid hormone-related protein (PTHrP) in
the milk and blood and increases calcium transport in
the milk. Conversely, in breast cancer, CaSR stimulates
the expression of PTHrP. A switch in the function of the
G-proteins underlies the opposite effects of CaSR on the
expression of PTHrP in normal and neoplastic mam-
mary epithelial cells.
Calcium-sensing receptor and cardiovascular risk
CaSR is present on the β cells and the enteral endocrine
cells, as well as on the adipocytes and the myocytes. This
may explain why alterations in cardiac function and
metabolic regulation are associated with genetically
determined signalling abnormalities of CaSR, particularly
with regard to insulin secretion, postprandial blood
glucose regulation, lipolysis and inhibition of myocardial
cell proliferation [57–63].
Calcium-sensing receptor and taste regulation
CaSR could participate in taste control (particularly the
taste of kokumi) and the regulation of enterogastric
hormones, such as ghrelin, which are orexigenic and par-
ticipate in glucose regulation in response to the amino acid
intake in the intestine [64].
Knowledge of the calcium-sensing receptor enables
the development of various approaches, especially those
of an imaging agent (Calhex-231) in parathyroid diseases
and perhaps in the medullary thyroid cancer.
Calcium-sensing receptor modulators
There are two known types of CaSR modulators: CaSR
agonists (or activators, still named calcimimetics) and
calcilytic antagonists (or inhibitors of the calcium-
sensing receptor) [48, 60, 65–67].
CaSR agonists or calcimimetics
These drugs are capable of making CaSR more sensitive
to serum calcium levels, thereby decreasing the parathy-
roid hormone and the serum calcium in hyperparathyr-
oidism, whether they are primary, secondary or neoplastic.
Two types have been described: type I, which is a direct
agonist, and type II, which is a positive allosteric activator.
Cinacalcet is a type II calcimimetic and thus results in a
risk of dose-dependent hypocalcaemia by reducing the
parathyroid hormone. In patients on dialysis, cinacalcet
reduces calcium, phosphorus and FGF23 levels, hyperpla-
sia of the parathyroids and bone remodelling, with a bone
gain of around 3% in the femur; it may diminish skeletal
fracture rates and the need for parathyroidectomy. It is
also indicated in primary hyperparathyroidism, parathy-
roid carcinomatosis, parathyromatosis, and refusal or
contraindications of parathyroid surgery.
The second generation type II calcimimetic, Velcalcetide
(AMG416) is currently under regulatory review.
Their benefits have also been discussed in patients
with arterial hypertension and vascular calcifications.
The R-568 or AMG641 calcimimetics are in fact capable
of increasing CaSR expression and decreasing mineral-
isation of the vascular smooth muscle cells, which could
have a beneficial effect on vascular calcifications [68].
Finally, the combination of cinacalcet with small doses
of vitamin D has been shown to be effective in slowing
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down the progression of vascular calcifications compared
with treatments using larger doses of vitamin D alone.
Calcilytic antagonists or inhibitors of the calcium-sensing
receptor
Calcilytics are CaSR antagonists that stimulate the secretion
of PTH and reduce renal excretion of calcium. They have
not been shown to be effective in osteoporosis, especially
post-menopausal osteoprosis. They could be indicated in
cases of idiopathic hypocalcaemia and hypercalciuria.
Future outlook and Conclusions
There are many CaSR diseases, but familial hypocalciuric
hypercalcaemia syndrome is the most common, even if
it may sometimes be associated with, depending on the
variant, a hypercalciuric tendency, thus posing problems
for the differential diagnosis with hyperparathyroidism.
The genetic causes identified in adults usually require no
treatment. Some cases of parathyroid adenomas, however,
are associated with CASR gene mutations, thus justifying
additional morphological investigations in case of severe
hypercalcaemia, since excision of these adenomas can
improve serum calcium levels.
The CASR gene might also be involved in tumourigen-
esis, particularly in the colon, breasts and the prostate,
as well as in cardiovascular and inflammatory diseases,
including both digestive and respiratory.
It is important to know how to make the diagnosis in
complex situations, such as mammary neoplasm or
chronic renal failure, since these disorders, which remain
asymptomatic for a long time, can suggest neoplastic
hypercalcaemia or that related to tertiary hyperparathyr-
oidism, while it is in fact a genetically determined
disorder.
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